

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human MMP-16/MT3-MMP in ELISAs. In direct ELISAs, no cross-reactivity with recombinant human MMP-14, -15, or -24 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2A</sub> Clone # 782005
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human MMP-16/MT3-MMP Ala32-Pro535 Accession # P51512
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Sterile PBS to a final concentration of 0.5 mg/mL.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Matrix metalloproteinases (MMPs) are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix (ECM). MMP-16 (MT3-MMP) is found in brain, lung, placenta, smooth muscle cells, and malignant tumor tissues including oral melanoma and renal carcinoma (1). MMP-16 has been shown to activate proMMP-2 and degrade various ECM components including native collagens (2, 3). MMP-16 has been proposed to possess the potential to directly enhance the growth and invasiveness of cells *in vivo*, two critical processes for development and carcinogenesis (4). Structurally, MMP-16 consists of the following domains: a pro domain containing the furin cleavage site, a catalytic domain containing the zinc-binding site, a hinge region, a hemopexin-like domain, a transmembrane domain, and a cytoplasmic tail (1). The structure of the catalytic domain in complex with a hydroxamate inhibitor has been solved (5).

## References:

1. Takino, T. *et al.* (1995) J. Biol. Chem. **270**:23013.
2. Shofuda, K. *et al.* (1997) J. Biol. Chem. **272**:9749.
3. Shimada, T. *et al.* (1999) Eur. J. Biochem. **262**:907.
4. Kang, T. *et al.* (2000) FASEB J. **14**:2559.
5. Lang, R. *et al.* (2004) J. Mol. Biol. **336**:213.